Exclusive contract

Quantum Pharma Plc

("Quantum", the "Company" or the "Group")

Exclusive contract with the UK's third largest pharmacy chain

Quantum Pharma Plc (AIM: QP), a growing manufacturer, supplier and service provider to the niche pharmaceutical sector, today announces that its wholly owned subsidiary Quantum Pharmaceutical or ("QPL"), the Group's core business, which manufactures and supplies Specials and Special Obtains to the majority of the large retail pharmacy chains and pharmaceutical wholesalers in the UK, hospitals, independent pharmacies and dispensing doctors, has signed a three year contract with Bestway Panacea Healthcare Limited ("Bestway"), a wholly owned subsidiary of Bestway Group, whereby QPL will be exclusive supplier of unlicensed medicines and Special Obtain products to Bestway's pharmacy stores.

Under the agreement, which formalises the existing trading relationships and is set to commence on 1 January 2015 with commercial negotiations to take place annually; QPL will supply each of Bestway's 774 pharmacy stores which currently trade under the Co-operative Pharmacy name with all unlicensed medicines and Special Obtain products. Co-operative Pharmacy was acquired by Bestway Group in October 2014 for £620 million.

Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "The signing of this contract marks the culmination and formalisation of years of work with Co-operative Pharmacy. Quantum Pharmaceutical has a service driven business model which enables us to provide shorter lead times for pharmacies across the UK which we believe will be of major benefit to Bestway.

"With 774 pharmacies located across the country, the Board is delighted to have won such an important and exclusive contract and we look forward to working with Bestway in the future as we continue to increase our customer base across the unlicensed medicine and Special Obtains market."

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a growing manufacturer, supplier and service provider to the wholesale and retail pharmacy, hospital, homecare and care home markets. Based in a purpose-built facility in Burnopfield, County Durham, the Group manufactures and sources non-standard pharmaceutical products. Formed in 2004, Quantum has grown significantly in recent years (both organically and by acquisition) and now employs over 320 people. The Group operates through five business units.

Quantum Pharmaceutical, the Group's core business, manufactures and supplies Specials and Special Obtains to the majority of the large retail pharmacy chains and pharmaceutical wholesalers in the UK, hospitals, independent pharmacies and dispensing doctors. Specials and Special Obtains are medicines and medicinal products that are difficult for pharmacies to source from wholesale pharmacy suppliers. Quantum has a product range of over 22,000 Special and Special Obtain products. It regularly services around 6,500 pharmacies and over 240 hospital accounts across the UK.

U L Medicines ("ULM") is a supplier of unlicensed imports (over 450 imported medicines), over 100 batch made Specials and bespoke Specials with a focus on the hospital market. ULM has a diverse customer base and supplies over 240 hospital accounts, as well as wholesalers and retail pharmacies in the UK and wholesalers overseas.

Colonis is a specialist pharmaceutical product development business, which focuses on achieving the relevant regulated status for medicines and medical devices. The development programme is currently working on a significant pipeline of products across 15 therapeutic areas.

Biodose is a patent protected medicine delivery system ("MDS") which consists of a tray, 28 medication pods and a seal, which is used to manage pre-prepared medication regimes for patients. These assist with patient specific medicine administration and adherence to medication regimes. The Biodose system is currently sold to around 175 pharmacy customers, through whom around 50,000 care home residents use Biodose.

Quantum Aseptics' facility at Burnopfield became operational in April 2013 after receiving an MHRA aseptic special manufacturing licence. This facility, which the Director's believe to be is one of the most advanced aseptics units in the UK, provides Quantum Aseptics (a division of Quantum Pharmaceutical) with the ability to aseptically prepare and supply intravenous dosage form aseptic products, whilst complementing the existing core business product offering by providing the ability to prepare these sterile Specials for the Group's other business units and third parties.

For further information, please visit www.quantumpharmaplc.com.